Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $256,436.66 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,546 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total value of $256,436.66. Following the completion of the transaction, the chief financial officer now directly owns 177,449 shares of the company’s stock, valued at $3,941,142.29. The sale was disclosed in a filing with the SEC, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 6th, Oluyemi Okupe sold 98,635 shares of Hims & Hers Health stock. The stock was sold at an average price of $21.42, for a total value of $2,112,761.70.

Hims & Hers Health Trading Down 7.2 %

NYSE:HIMS opened at $20.01 on Friday. The stock has a fifty day simple moving average of $17.42 and a 200 day simple moving average of $13.41. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.05) earnings per share. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.19 EPS for the current year.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently modified their holdings of HIMS. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at $86,836,000. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at about $8,232,000. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 3.1% in the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 39.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company’s stock worth $8,006,000 after purchasing an additional 357,590 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Bank of America increased their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. Finally, Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.